Mednet Logo

How do you decide about neoadjuvant chemotherapy in a women with both IDC and DCIS on biopsy when the tumor is ill defined on imaging?

NCCN recommendations seem to mention these patients as not candidates for preoperative systemic therapy if the invasive carcinoma extension cannot be delineated from extensive DCIS.
2 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · NYU Langone Medical Center
Answered on

In the clinical scenario of a palpable tumor and biopsy reflecting a mix of pre-invasive disease (DCIS) and proliferative cancer, the value of neoadjuvant chemotherapy is debatable. The optimal goal of NAC is to ameliorate long term outcome, that was documented with pCR, these quite low in original ...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · University of Iowa Holden Comprehensive Cancer Center
Answered on

I would say the answer depends on the subtype of Invasive breast cancer. I would be fine considering Neo-adjuvant systemic therapy in the setting of TNBC and Her 2 Positive breast cancer as I would not be doing any harm even if invasive component is really small like only about 5 mm

I would not gi...

Join for free or sign in to see the full answer